- Joined
- May 11, 2006
- Messages
- 459
- Reaction score
- 3
Shocking!
Interventional cardiologists still raking in the money
WSJ argues COURAGE is a missed opportunity for comparative effectiveness savings
FEBRUARY 12, 2010 | Reed Miller
New York, NY - The failure of the cardiology community to rein in stenting rates following the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial is an example of a missed opportunity for the US healthcare system to capitalize on the sort of comparative effectiveness research that is set to get $1.1 billion in funding under the healthcare insurance reform bills now before Congress, according to an article in the February 11, 2010 Wall Street Journal [1].
As reported by heartwire, results of the 2287-patient COURAGE trial, published in the New England Journal of Medicine in 2007, showed that coronary stenting with optimal medical therapy is no better at preventing future coronary events than optimal medical therapy alone in patients with stable coronary disease.
In the article, WSJ reporter Keith J Winstein suggests that the COURAGE results have failed to change clinical practice as much as the results suggest they should because the economic incentives for interventionalists and insurance companies favor stenting over medical therapy.
The article quotes Dr Sanjay Kaul (Cedars-Sinai Heart Institute, Los Angeles, CA), who estimates that by not stenting the patients COURAGE showed do not benefit from stents, the US healthcare system could save $5 billion of the $15 billion a year it spends on stent procedures.
As reported in heartwire, Medicare data show that, contrary to professional guidelines, most patients getting a stent do not have a stress test to prove they urgently need the stent. The Journal quotes theheart.org editor-in-chief Dr Eric Topol (Scripps Translational Science Institute, La Jolla, CA) as stating, "It's certainly remarkable that nothing has been done to put some checks and balances" into stenting practices in light of COURAGE. "I have a very strong disagreement with cardiologists who see no reason to do the stress test."
The WSJ states that interventional cardiologists have an incentive to implant stents because they receive $900 per procedure, while the only revenue they get from prescribing drugs is about $100 for an office visit.
The article points out that neither Medicare nor private insurers have changed their coverage policies in light of COURAGE. "There's no incentive on the part of the insurance company to do that," Dr George Diamond (Cedars-Sinai Medical Center, Los Angeles, CA) says in the article. "[It] would cause an uproar on the part of the physicians saying insurance companies were attempting to interpose themselves on the medical process."
However, according to the article, Blue Cross/Blue Shield plans in western and northeastern New York State recently began requiring stress tests prior to stenting to verify a stent is necessary to preserve coronary flow, and the plans will soon require that patients try drug therapy for three months before elective stenting for chronic chest pain.
http://www.theheart.org/article/1047209.do
Interventional cardiologists still raking in the money
WSJ argues COURAGE is a missed opportunity for comparative effectiveness savings
FEBRUARY 12, 2010 | Reed Miller
New York, NY - The failure of the cardiology community to rein in stenting rates following the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial is an example of a missed opportunity for the US healthcare system to capitalize on the sort of comparative effectiveness research that is set to get $1.1 billion in funding under the healthcare insurance reform bills now before Congress, according to an article in the February 11, 2010 Wall Street Journal [1].
As reported by heartwire, results of the 2287-patient COURAGE trial, published in the New England Journal of Medicine in 2007, showed that coronary stenting with optimal medical therapy is no better at preventing future coronary events than optimal medical therapy alone in patients with stable coronary disease.
In the article, WSJ reporter Keith J Winstein suggests that the COURAGE results have failed to change clinical practice as much as the results suggest they should because the economic incentives for interventionalists and insurance companies favor stenting over medical therapy.
The article quotes Dr Sanjay Kaul (Cedars-Sinai Heart Institute, Los Angeles, CA), who estimates that by not stenting the patients COURAGE showed do not benefit from stents, the US healthcare system could save $5 billion of the $15 billion a year it spends on stent procedures.
As reported in heartwire, Medicare data show that, contrary to professional guidelines, most patients getting a stent do not have a stress test to prove they urgently need the stent. The Journal quotes theheart.org editor-in-chief Dr Eric Topol (Scripps Translational Science Institute, La Jolla, CA) as stating, "It's certainly remarkable that nothing has been done to put some checks and balances" into stenting practices in light of COURAGE. "I have a very strong disagreement with cardiologists who see no reason to do the stress test."
The WSJ states that interventional cardiologists have an incentive to implant stents because they receive $900 per procedure, while the only revenue they get from prescribing drugs is about $100 for an office visit.
The article points out that neither Medicare nor private insurers have changed their coverage policies in light of COURAGE. "There's no incentive on the part of the insurance company to do that," Dr George Diamond (Cedars-Sinai Medical Center, Los Angeles, CA) says in the article. "[It] would cause an uproar on the part of the physicians saying insurance companies were attempting to interpose themselves on the medical process."
However, according to the article, Blue Cross/Blue Shield plans in western and northeastern New York State recently began requiring stress tests prior to stenting to verify a stent is necessary to preserve coronary flow, and the plans will soon require that patients try drug therapy for three months before elective stenting for chronic chest pain.
http://www.theheart.org/article/1047209.do